Compare Becton Dickinson and Co (BDX) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Five Below Inc — how do they compare? Becton Dickinson and Co trades at $180.76 (market cap $48.93B), while Five Below Inc trades at $234.98 (market cap $13.01B). The key difference: Becton Dickinson and Co is far larger — about 3.8× Five Below Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Five Below Inc pays none. Which is the better fit depends on your goals.
| BDX | FIVE | |
|---|---|---|
Market Cap | $48.93B | $13.01B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $247.71 |
52-Week Low | $138.62 | $131.94 |
Enterprise Value | $65.03B | $13.90B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Five Below (FIVE) is trading at $244.37, up 5.73% with strong bullish momentum. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.22 exceeding expectations of $1.77. Technical indicators signal bullish sentiment, supported by positive moving averages. Revenue growth remains solid, projected to reach $5.1B in 2026, though net margins have compressed from 9.78% in 2022 to 6.54% in 2025. Analyst consensus is strongly bullish with 62% buy ratings and a $252.36 price target.
FIVE presents a compelling growth story with expanding revenue and strong institutional support. However, elevated valuation multiples (P/E 30.79) and compressed profit margins pose risks. The stock's proximity to 52-week highs suggests limited near-term upside without significant catalysts. Execution on store expansion and margin improvement will be critical for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
